3Capsoni S, Ugolini G, Comparini A, et al. Alzheimer-like neurodcgeneration in aged antinerve growth factor transgenic mice[J]. Proc Natl Acad Sci USA,2000,97(12):6826-6831.
4Schenk D, Barbour R, Dunn W, et al. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse[J]. Nature, 1999,400(6740) : 173-177.
5Morgan D, Diamond DM, Gottschall PE, et al. A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease[J]. Nature, 2000,408(6815) : 982-985.
6Janus C, Pearson J, McLaurin J, et al. A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease[J]. Nature, 2000,408 (6815) : 979- 982.
7Lemere CA, Beierschmitt A, Iglesias M, et al. Alzheimer's disease abeta vaccine reduces central nervous system abeta levels in a non-human primate, the Caribbean vervet[J]. Am J Pathol, 2004,165 (1) : 283-297.
8Bard F, Cannon C, Barbour R, et al. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease[J]. Nat Med,2000,6(8) :916-919.
9Kotilinek LA, Bacskai B, Westerman M, et al. Reversible memory loss in a mouse transgenie model of Alzbeimer's disease [J]. J Neurosci,2002,22(15):6331-6335.
10Wilcock DM, Rojiani A, Rosenthal A, et al. Passive immunotherapy against Abeta in aged APP-transgenic mice reverses cognitive deficits and depletes parenchymal amyloid deposits in spite of increased vascular amyloid and microhemorrhage[J]. J Neuroinflammation, 2004,1 (1) : 24.
二级参考文献42
1Mayeux R. Epidemiology of neurodegeneration[J]. Annu Rev Neurosci, 2003,26 (1) 81-104.
2Jun G, Naj A C, Beecham G W, et al. Meta-analysis confirms CR1, CLU, and PICALM as Alzheimer disease risk loci and reveals interactions with APOE genotypes[J]. Arch Neurol, g010,67(12) :1473-1484.
3Chu L W, Tam S, Wong R L, et al. Bioavailable testosterone predicts a lower risk d Alzheimer's disease in older men[J]. J Alzheimers Dis,2010,21(4) : 1335-1345.
4Hardy J. The amyloid hypothesis for Alzheimer's disease: a critical reappraisal[J]. J Neurochem, 2009,110(4) : 1129 1134.
5Chiu K C, Chu L W, Chung C P, et al. Clinical features of Alzheimer's disease in a regional memory clinic in Hong Kong [J]. J Hong KongGeriatr Soc,2002,11(1):21-27.
6McKhann G M, Knopman D S, Chertkow H, et aZ. The diagnosis of dementia due to Alzheimer's disease : recommendations from the National Institute on Aging- Alzheimer's Association Workgroups on Aiagnostic Duidelines for Alzheimer's Disease[J]. Alzheimers Dement, 2011,7 ( 1 ) : 263-269.
7Mak H K, Zhang Z, Yau K K, et al. Efficaey of voxel based morphometry with DARTEL and standard registration as imaging biomarkers in Alzheimer's disease patients and cognitively normal older adults at 3.0 Tesla MR imaging[J]. J Alzheimers Dis,2011,23(4) :655 664.
8Tartaglia M C, Rosen H J, Miller 13 L. Neuroimaging in dementia[J]. Neurotherapeutics, 2011,8 (1) : 82-92.
9Morris J C, Roe C M, Grant E A, etal. Pittsburgh compound B imaging and prediction of progression {rom cognitive normality to symptomatic Alzheimer disease[J]. Arch Neurol, 2009,66(12) 1469-1475.
10Fjell A M, Walhovd K B, Fennema-Notestine C, et al. CSF biomarkers in prediction of cerebral and clinical change in mild cognitive impairment and Alzheimer's disease[J]. J Neurosci, 2010,30(6) :2088-2101.
